- Parties: The applicants were Novartis Pharmaceuticals Canada Inc. and  Novartis AG. The respondent was Zydus Lifesciences Limited. 

- Subject Matter: This Federal Court matter involves an action brought pursuant to subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations, in which the Plaintiffs Novartis Pharmaceuticals Canada Inc. and Novartis AG allege that the Defendant Zydus Lifesciences Limited's generic sacubitril/valsartan product (ZDS-SACUBITRIL AND VALSARTAN), filed under Abbreviated New Drug Submission Number 301464, would directly infringe or induce the infringement of asserted claims of Canadian Patent No. 2,590,511 and Canadian Patent No. 2,703,598. The Defendant has filed a Statement of Defence denying infringement and challenging the validity of the asserted claims on multiple grounds including obviousness, insufficiency, overbreadth, lack of utility, and anticipation, and has indicated it will seek a summary trial on infringement issues relating to the 598 Patent. The case is ongoing.

- Date: The hearing was set on April 30, 2026.

- Venue: This was a federal case before the Federal Court.

- Amount: No financial award was specified.